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Background: Toll-like receptors (TLRs) have been implicated in myocardial ischemia/reperfusion (I/R) injury.
The TLR9 ligand, CpG-ODN has been reported to improve cell survival. We examined effect of CpG-ODN on
myocardial I/R injury. Methods: Male C57BL/6 mice were treated with either CpG-ODN, control-ODN, or
inhibitory CpG-ODN (iCpG-ODN) 1 h prior to myocardial ischemia (60 min) followed by reperfusion. Untreated
mice served as I/R control (n=10/each group). Infarct size was determined by TTC straining. Cardiac function
was examined by echocardiography before and after myocardial I/R up to 14 days. Results: CpG-ODN
administration signiﬁcantly decreased infarct size by 31.4% and improved cardiac function after myocardial I/R
up to 14 days. Neither control-ODN nor iCpG-ODN altered I/R-induced myocardial infarction and cardiac
dysfunction. CpG-ODN attenuated I/R-induced myocardial apoptosis and prevented I/R-induced decrease in
Bcl2 and increase in Bax levels in the myocardium. CpG-ODN increased Akt and GSK-3β phosphorylation in the
myocardium. In vitro data suggested that CpG-ODN treatment induced TLR9 tyrosine phosphorylation and
promoted an association between TLR9 and the p85 subunit of PI3K. Importantly, PI3K/Akt inhibition and Akt
kinase deﬁciency abolished CpG-ODN-induced cardioprotection. Conclusion: CpG-ODN, the TLR9 ligand,
induces protection against myocardial I/R injury. The mechanisms involve activation of the PI3K/Akt
signaling pathway.© 2012 Elsevier B.V. All rights reserved.1. Introduction
The innate immune and inﬂammatory responses are involved in
myocardial ischemia/reperfusion (I/R) injury [5,12,19,26]. Toll-like
receptors (TLRs) play a critical role in the induction of innate immune
and inﬂammatory responses [1]. Recent studies have demonstrated
that TLRs could be the target as a new treatment approach for myo-
cardial I/R injury. We and other investigators have previously reported
that TLR4 deﬁciency or modulation of TLR4 mediated signaling pro-
tected the myocardium from ischemic injury [4,5,12,19,26,30]. TLR2
is also implicated in myocardial I/R injury [2,9,24,28]. In addition,
administration of ligands for TLR2 [6,9,13,24], TLR4 [10], and TLR9 [32]
induces a protection against ischemic injury in heart [6,10,24] and brain
[13,32] through a preconditioning mechanism.ast Tennessee State University,
el.: +1 423 439 6349; fax: +1
l rights reserved.TLR9 is located intracellularly in endosomes and endoplasmic reticu-
lum and recognizes unmethylated CpG-DNA from bacteria and endog-
enous DNA [18]. CpG-motifs activate the TLR9-mediated MyD88-
dependent NF-κB signaling pathway and mitogen activated protein
kinases (MAPKs) [18]. Synthetic CpG-oligodeoxynucleotide (ODN) has
been demonstrated to activate TLR9 [17,18], improve cell survival and
prevent cell apoptosis [29]. Recently, several studies reported a beneﬁt of
CpG-ODN in sepsis and cardiac function after I/R. Rice et al. [27] and
Weighardt et al. [34] have shown that treatment of experimental
animals with CpG-ODN improved polymicrobial sepsis survival rate.
Mathur et al. showed that pretreatment ofmicewith CpG-C isoform24 h
prior to endotoxin challenge improved ejection fraction 6 h after LPS
stimulation [21]. Pretreatment of mice with CpG-C isoform 24 h prior to
myocardial I/R improved ejection fraction after myocardial I/R [21]. The
protection induced by 24 h pretreatment is through preconditioning
dependent mechanisms. However, the role of B-isoform of CpG-ODN in
myocardial I/R injury has not been investigated. In addition, the
mechanisms by which CpG-ODN exerts the protective beneﬁts have
not been elucidated.
Phosphoinositide 3-kinases (PI3Ks), and their downstream target
serine/threonine kinase Akt [also known as protein kinase B (PKB)],
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involved in regulating cellular activation, inﬂammatory responses,
and apoptosis [3]. The PI3K/Akt signaling pathway may serve as an
endogenous negative feedback regulator and/or compensatory mech-
anism that limits pro-inﬂammatory and apoptotic events in response
to injurious stimuli. Activation of PI3K/Akt-dependent signaling has
been shown to prevent cardiac myocyte apoptosis and protect the
myocardium from I/R injury [7,22]. Recent studies have identiﬁed
cross talk between TLR signaling and the PI3K/Akt pathway [25].
In the present study, we examined the effect of CpG-ODN
on myocardial I/R injury. We have observed that administration of
CpG-ODN 1 h prior to myocardial I/R signiﬁcantly reducedmyocardial
infarct size and improved cardiac function after myocardial I/R injury.
We demonstrated that CpG-ODN-induced cardioprotection was
mediated by a PI3K/Akt signaling dependent mechanism.
2. Materials and methods
2.1. Animals
Male C57BL/6 mice (25–30 g) were obtained from Jackson
Laboratory (Indianapolis, IN). Transgenic mice with cardiac speciﬁc
expression of kinase defective Akt (kdAkt) with an FVB background
were provided by Dr. McMullen and have been described previously
[31]. The mice were maintained in the Division of Laboratory Animal
Resources at East Tennessee State University. The experiments out-
lined in this article conform to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of Health
(NIH Publication No. 85-23, Revised 1996). All aspects of the animal
care and experimental protocols were approved by the East Tennessee
State University Committee on Animal Care.
2.2. Induction of myocardial I/R injury
Myocardial I/R injury was induced as described previously
[9,10,12,19]. Brieﬂy, the mice were anesthetized by 5.0% isoﬂurane,
intubated and ventilated with room air using a rodent ventilator.
Anesthesia was maintained by inhalation of 1.5% to 2% isoﬂurane
driven by 100% oxygen ﬂow. Body temperature was regulated at
37 °C by surface water heating. Following the skin incision, the hearts
were exposed through a left thoracotomy in the fourth intercostal
space. The left anterior descending (LAD) coronary artery was ligated
with an 8-0 silk ligature over a 1 mm polyethylene tube (PE-10). After
completion of 60 min of occlusion, the coronary artery was reper-
fused by pulling on the exteriorized suture to release the knot. The
skin was closed, anesthesia discontinued, and the animal allowed to
recover in pre-warmed cages. After reperfusion for indicated time,
the mice were sacriﬁced by CO2 inhalation and the hearts were
harvested.
2.3. Experimental protocol
To examine the role of TLR9 activation in myocardial I/R injury, we
employed the TLR9 ligand, CpG-ODN. The mice were treated with
CpG-ODN (n=10, 10 μg/25 g body weight) or control-ODN (n=10,
10 μg/25 g body weight) by intraperitoneal injection 1 h before the
hearts were subjected to I/R. To evaluate the role of TLR9 inactivation
in myocardial I/R injury, we chose inhibitory CpG-ODN (iCpG-ODN)
which binds C-terminal fragment of TLR9 resulting in preventing
TLR9 activation [36]. iCpG-ODN (100 μg/25 g body weight) was
administered to the mice (n=10) by i.p. injection 1 h prior to myo-
cardial I/R. Mice that did not receive any treatment served as untreated
controls. The dose of CpG-ODN used in the present study was selected
based onour pilot study using 10, 50, 75 and100 μg/25 g bodyweight of
CpG-ODN. We observed that administration of CpG-ODN at 10 μg/25 g
body weight also signiﬁcantly decreased myocardial infarct size. TheCpG-ODN (CpG-ODN 1826), Control ODN (control-ODN 1826), and
iCpG-ODN (iCpG-ODN 2088) were purchased from InvivoGen (San
Diego, CA).
We also examined the effect of CpG-ODN on cardiac function
following myocardial I/R injury. The mice (n=5 each group) were
treated with and without CpG-ODN, control-ODN or iCpG-ODN 1 h
before the hearts were subjected to 60 min of ischemia followed
by reperfusion up to 14 days. Cardiac function was examined by
echocardiography before I/R, 3 and 14 days after reperfusion as
described previously [9,11].
To determine the role of the PI3K/Akt signaling pathway in TLR9
ligand-induced cardioprotection, the mice (n=8) were injected with
the PI3K inhibitor LY924002 (I mg/25 g body weight, Sigma-Aldrich,
St Louis, MO) 15 min prior to CpG-ODN administration (10 μg/25 g
body weight). In a separate experiment, kdAkt transgenic mice (n=6
each group) were treated with or without CpG-ODN 1 h before the
hearts were subjected to I/R [9,10].
2.4. Assessment of myocardial infarct size
Infarct size was evaluated by TTC (Sigma-Aldrich) staining as
described previously [9,10,12,19]. Brieﬂy, the hearts were perfused
with saline on a Langendorff system to wash blood from the coronary
vasculature before staining with 1% Evans Blue. Each heart was then
sliced horizontally to yield ﬁve slices. The slices were incubated in 1%
TTC for 15 min at 37 °C, ﬁxed by immersion in 10% neutral buffered
formalin. The area of infarction on both sides of each slice was
determined by an image analyzer, corrected for the weight of each
slice, and summed for each heart. Ratios of risk area vs. left ventricle
area (RA/LV) and infarct area vs. risk area (IA/RA) were calculated
and expressed as a percentage.
2.5. Echocardiography
Transthoracic two-dimensional M-mode echocardiogram and
pulsed wave Doppler spectral tracings were obtained using a Toshiba
Aplio 80 Imaging System (Tochigi, Japan) equipped with a 12-MHz
linear transducer as described previously [9,11]. The mice were
anesthetized by isoﬂurane and the body temperature was maintained
at 37 °C using a heating pad. M-mode tracings were used to measure
left ventricular (LV) wall thickness, LV end-systolic diameter
(LVESD), and LV end-diastolic diameter (LVEDD). Ejection fraction
(EF) and percent fractional shortening (%FS) were calculated as
described previously [9,11].
2.6. In situ apoptosis assay
Myocardial apoptosis was examined as described previously
[9,10,12,19] using the in situ cell death detection kit, ﬂuorescein
(Roche, USA) according to the instructions of the manufacturer.
Brieﬂy, hearts were harvested 4 h after reperfusion and slices cut
horizontally. One slice was immersion-ﬁxed in 4% buffered parafor-
maldehyde, embedded in parafﬁn and cut at 5 μm thick. The sections
were incubated with the commercially prepared labeling mixture
supplied by the manufacturer at 37 °C for 1 h. Nuclei of living and
apoptotic cells were counterstained with Hoechst 33342 (Invitrogen).
Three slides from each block were evaluated for percentage of
apoptotic cells and four ﬁelds on each slide were examined at the
border areas using a deﬁned rectangular ﬁeld area with 20×
magniﬁcation. Numbers of apoptotic cardiac myocytes are presented
as the percentage of total cells counted.
2.7. Immunoblot
Immunoblots were performed as described previously [9,10,12,19].
Brieﬂy, hearts were harvested 4 h after reperfusion. The cellular
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antibodies used in the present study were anti-phospho-Akt, anti-
phospho-GSK-3β (anti-Ser9), anti-ERK, anti-Akt, anti-GSK-3β and anti-
ERK (1:500, Cell Signaling Technology Beverly,MA), anti-BcL2, anti-Bax,
anti-phosphotyrosine (anti-pTyr20), anti-TLR9, and anti-p85 subunit
of PI3K (1:1000, Santa Cruz), anti-GAPDH (1:8000, Biodesign). The
secondary antibodieswere anti-rabbit and anti-mouse (Sigma-Aldrich).
The signals were detectedwith the ECL system (Amersham Pharmacia).
The signals were quantiﬁed using the G:Box gel imaging system by
Syngene (Syngene, USA, Fredrick, MD).
2.8. In vitro experiments
The H9C2 rat cardiomyoblasts were purchased from the American
Type Culture Collection (ATCC, Rockville, MD) and were maintained
in Dulbecco's Modiﬁed Eagle's Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) under 5% CO2 at 37 °C. When
cells reached 70–80% conﬂuence, they were treated with CpG-ODN
(50 nM), control-ODN (50 nM), in the presence and absence of
LY924002 (10 μM) for 30 min, respectively. Each group contained
four replicates. The cells were harvested and cellular proteins were
prepared for immunoprecipitation and Western blot analysis as
described previously [9,19].
2.9. Immunoprecipitation
Approximately 800 μg of cellular proteins was immunoprecipi-
tated with 2 μg of antibody against TLR9 (Santa Cruz, Biotechnology,
Inc., CA) for 2 h at 4 °C on a rotator followed by addition of 20 μl
protein A/G-agarose beads (Santa Cruz) as described previously
[9,19]. The immunoprecipitations were washed three times in lysis
washing buffer, suspended in 25 μl of loading buffer, and boiled for
5 min before the immunoprecipitates were subjected to immunoblots
with primary antibodies (anti-pTyr20, 1:500, and anti-p85, 1:500,
Santa Cruz), respectively, followed by secondary antibody (anti-
rabbit and anti-mouse, Sigma-Aldrich).
2.10. Statistical analysis
Data are expressed as mean±SE. Comparisons of data between
groups were made using one-way analysis of variance (ANOVA), and
Tukey's procedure for multiple-range tests was performed. Pb0.05
was considered to be signiﬁcant.
3. Results
3.1. CpG-ODN administration reduced myocardial infarction and
improved cardiac function following I/R
To investigate the effect of TLR9 ligand, CpG-ODN, on myocardial
infarction following I/R, we administered CpG-ODN to the mice 1 h
prior to myocardial ischemia (60 min) followed by reperfusion (4 h).
Fig. 1A shows that CpG-ODN treatment signiﬁcantly reduced infarct
size by 31.3% compared with untreated I/R hearts (15.3±1.15% vs.
22.2±1.38%). There was no signiﬁcant difference in the ratio of risk
area/left ventricle area (RA/LV) between CpG-ODN-treated mice and
untreated I/R mice, suggesting that the coronary artery was ligated in
the same place between the groups (Fig. 1A). Administration of either
control-ODN or iCpG-ODN to the mice did not alter I/R-induced
myocardial infarction.
We also examined the effect of CpG-ODN on cardiac function
following myocardial I/R. Fig. 1B shows that ejection fraction (EF%)
and fractional shortening (%FS) were signiﬁcantly decreased after
myocardial ischemia followed by reperfusion up to 14 days. In contrast,
CpG-ODN administration attenuated I/R-induced cardiac dysfunction.
EF and %FS values in CpG-ODN-treated mice were signiﬁcantlyincreased by 48.3% and by 56.9% at 3 days, and by 37.0% and by 50.7%
at 14 days after reperfusion, respectively, compared with untreated I/R
mice. Treatment of mice with either control-ODN or iCpG-ODN did not
affect I/R-induced cardiac dysfunction.
3.2. CpG-ODN administration attenuated I/R-increased myocardial
apoptosis
It iswell known thatmyocardial apoptosis contributes tomyocardial
ischemic injury. We examined the effect of CpG-ODN treatment on I/R-
induced myocardial apoptosis. Fig. 2 shows that I/R markedly induced
myocardial apoptosis. In contrast, CpG-ODN administration signiﬁcantly
attenuated I/R-induced myocardial apoptosis by 46.6% compared with
untreated I/R hearts. Control-ODN administration did not affect I/R-
induced apoptosis in the myocardium (data not shown).
3.3. CpG-ODN administration attenuated I/R-decreased BCL-2 and
increased Bax levels in the myocardium
We investigated whether CpG-ODN-attenuated myocardial apo-
ptosis will be involved in regulation of Bcl2/Bax mediators. Fig. 3
shows that I/R signiﬁcantly decreased Bcl-2 levels by 47.3% and
increased Bax levels by 48.9% in the myocardium compared with
sham control. The ratio of Bax/Bcl2 in untreated I/R mice was
increased by 175% compared with sham control. In contrast, CpG-
ODN treatment prevented I/R-decreased Bcl2 levels and attenuated
I/R-increased Bax levels in the myocardium observed in untreated I/R
hearts. I/R-increased ratio of Bax/Bcl2 was attenuated by CpG-ODN
administration. In control-ODN treated I/R mice, the levels of Bcl2
and Bax were similar to that of untreated I/R mice.
3.4. CpG-ODN increased the levels of phosphorylated Akt, GSK-3-β and
ERK in the myocardium following myocardial I/R
Activation of the PI3K/Akt signaling pathway has been shown to
protect the myocardium from ischemic injury [10,19,22]. We
examined whether CpG-ODN administration will induce the activa-
tion of PI3K/Akt signaling in the myocardium following I/R. Fig. 4
shows that CpG-ODN treatment signiﬁcantly increased the levels
of phospho-Akt by 2.3 fold and phospho-GSK-3β by 2.2 fold, respec-
tively, compared with the untreated I/R group. CpG-ODN also
increased the levels of ERK phosphorylation by 35% compared with
untreated I/R hearts. Control-ODN administration did not signiﬁcantly
alter the levels of phospho-Akt, phospho-GSK-3β and phospho-ERK in
the myocardium of untreated sham and I/R mice. Treatment of mice
with a speciﬁc PI3K inhibitor, LY924002, abolished CpG-ODN-increased
levels of p-Akt and p-GSK-3β in the myocardium.
3.5. CpG-ODN treatment induced TLR9 phosphorylation and association
with the p85 subunit of PI3K
To determine the mechanisms by which CpG-ODN administration
increased myocardial phospho-Akt, we performed in vitro experi-
ments using the cultured cardiomyoblast H9C2 cell line. H9C2 cells
were treated with CpG-ODN for 15 min and the cells were then
harvested. The cellular proteins were isolated for analysis of Akt
phosphorylation. Fig. 5A shows that CpG-ODN treatment increased
the levels of phospho-Akt compared with untreated cells (0.57±0.06
vs 0.30±0.06). Control-ODN did not markedly induce Akt phos-
phorylation in H9C2 cells. PI3K inhibition by LY924002 abolished
CpG-ODN-induced Akt phosphorylation, indicating that CpG-ODN-
increased Akt phosphorylation is mediated by activation of PI3K.
Next, we examined whether there is an association between TLR9
and PI3K following CpG-ODN treatment. H9C2 cells were treated
with CpG-ODN for 15 min and cellular proteins were isolated for
immunoprecipitation with anti-TLR9 speciﬁc antibody followed by
Fig. 1. (A) TLR9 ligand, CpG-ODN, decreased myocardial infarct size following I/R injury. The mice were treated with CpG-ODN (n=10) or control CpG-ODN (n=10) or inhibitory
CpG-ODN (iCpG-ODN, n=10) by i.p. injection 1 h prior to myocardial ischemia (60 min) followed by reperfusion (4 h). The infarct area (white) and the area at risk (red+white)
from each section were measured using an image analyzer. Ratios of risk area vs. left ventricle area (RA/LV) and infarct area vs. risk area (IA/RA) were calculated and are presented
in the graph. *Pb0.05 compared with indicated group.(B) CpG-ODN administration improved cardiac function following myocardial I/R. The mice were treated with CpG-ODN
(n=5/group) 1 h before the hearts were subjected to myocardial ischemia (60 min) followed by reperfusion. Cardiac function was examined by echocardiography before I/R
(baseline), 3 days and 14 days after I/R. *Pb0.05 compared with indicated groups.
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ODN administration increased the levels of TLR9 tyrosine phosphory-
lation by 38.5% and association with the p85 subunit of PI3K byFig. 2. CpG-ODN administration attenuated I/R-increased myocardial apoptosis. The mice w
I/R. The hearts were harvested and sectioned for analysis of apoptosis by the TUNEL assay on
by red arrows. Blue color indicates the nucleus of each cell.*Pb0.05 compared with indicat110%, respectively, compared with untreated cells. The data suggests
that CpG-ODN treatment activated the PI3K/Akt signaling through
promoting the association of TLR9 and PI3K.ere treated with or without CpG-ODN (n=5/group) and were subjected to myocardial
the border zones. Green color indicates positive myocardial apoptosis which is marked
ed groups. S = Sham; I/R = ischemia/reperfusion.
Fig. 3. CpG-ODN treatment prevented I/R-decreased Bcl2 levels and attenuated I/R-increased Bax levels in the myocardium. The mice were treated with or without CpG-ODN or
control-ODN 1 h prior to myocardial I/R (n=6/group). Sham operated mice served as sham control (n=4). Cytoplasmic proteins were isolated from heart tissues for Western blot
analysis of Bcl2 (A), Bax (B) and the ratio of Bax/Bcl2 (C) levels. *Pb0.05 compared with indicated groups. S = Sham; I/R = ischemia/reperfusion.
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To determine the role of the PI3K/Akt signaling pathway in CpG-
ODN-induced cardioprotection, we treated the mice with LY924002, a
PI3K inhibitor, 15 min prior to CpG-ODN administration. The hearts
were subjected to ischemia (60 min) followed by reperfusion (4 h).
Fig. 6A shows that LY924002 administration abolished CpG-ODN-
induced cardioprotection. Infarct size in CpG-ODN-treated mice in the
presence of LY924002 was signiﬁcantly increased compared with
CpG-ODN treated mice that did not receive LY924002 (24.6±2.23%
vs.15.3±1.15%). There was no signiﬁcant difference in the infarct
size between the CpG-ODN+LY924002 group and the untreated I/R
group.
3.7. Genetic deﬁciency of Akt abrogated CpG-ODN-induced
cardioprotection
Akt is an important kinase downstream from PI3K [3]. To further
determine the role of the PI3K/Akt signaling in CpG-ODN-induced
cardioprotection, we examined the effect of Akt deﬁciency on CpG-
ODN-induced cardioprotection using mice that express a kinase
deﬁcient form of Akt (kdAkt) in cardiac myocytes. CpG-ODN was
administered to kdAkt transgenic mice 1 h before the hearts were
subjected to I/R. Untreated kdAtk Tg mice were subjected to I/R.
Fig. 6B shows that CpG-ODN administration to kdAkt mice did not
induce cardioprotection against I/R injury. The infarct size/area at risk
in CpG-ODN-treated kdAkt mice was similar to that of kdAkt I/R micethat did not receive CpG-ODN treatment. The data indicates that
CpG-ODN-induced cardioprotection was abolished in kdAkt mice.
4. Discussion
A major ﬁnding in the present study is that administration of a
TLR9 agonist, CpG-ODN, to the mice decreased infarct size and
improved cardiac function after myocardial I/R injury. Administration
of inhibitory CpG-ODN, the TLR9 antagonist, did not affect I/R-
induced myocardial infarction, suggesting that activation of TLR9
serves a protective role during myocardial I/R injury. More signiﬁ-
cantly, CpG-ODN treatment activated the PI3K/Akt signaling pathway
through induction of TLR9 tyrosine phosphorylation and association
with the p85 subunit of PI3K. Either PI3K inhibition with a speciﬁc
PI3K inhibitor, LY924002, or genetic inactivation of Akt in cardiac
myocytes abolished CpG-ODN-induced cardioprotection. The data
suggests that the TLR9 agonist, CpG-ODN, induces cardioprotection
involving activation of the PI3K/Akt signaling pathway.
There are several isoforms of CpG-ODNs including A-, B-, and
C-classes. These isoforms of CpG-ODN contain different CpG sequence
motifs and palindromic sequences [33]. A isoform effectively stim-
ulates the production of high amounts of IFN-alpha, while B isoform
primarily induces a strong activation and proliferation of B cells. C
isoform of CpG-ODNs has both the immune effects of A and B
isoforms but with lower effective [33]. A recent study by Mathur et al.
has investigated the effect of the three isoforms of CpG (A, B, and C)
on endotoxin-induced cardiac dysfunction [21]. The authors have
Fig. 4. CpG-ODN treatment increased the levels of phosphorylated Akt, GSK-3β and ERK in the myocardium. The mice were treated with or without CpG-ODN 1 h prior to
myocardial I/R (n=6/group). Sham operated mice served as sham control (n=4). A PI3K inhibitor, LY294002 was also administered to the mice (n=6/group) treated with and
without CpG-ODN. Cytoplasmic proteins were isolated from heart tissues forWestern blot analysis of phosphorylated Akt (A), phosphorylated GSK-3β (B), and phosphorylated DRK
(C). *Pb0.05 compared with indicated groups. U = Untreated; I/R = ischemia/reperfusion; LY = LY294002.
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induced cardiac dysfunction. In addition, pretreatment of mice with
CpG-C isoform at 100 μg/mouse 24 h before the hearts were subjected
to I/R prevented I/R-decreased ejection fraction [21]. In the present
study, we employed CpG-ODN 1826 which is the CpG‐B isoform.
Our data showed that administration of CpG-ODN B isoform at
10 μg/mouse 1 h prior to myocardial I/R induced a protection against
myocardial I/R injury and attenuation of I/R-induced cardiac dys-
function. We chose B isoform of CpG-ODN in the present study
because it has been reported to protect cells against spontaneous
apoptosis [29]. In addition, we have recently reported that this CpG-
ODN prevented trauma-hemorrhage induced cardiac dysfunction [37].
Our results were different from Mathur's study. First, we employed
CpG-B isoform (1826) in our present study while Mathur et al. used
CpG-C isoform in their study [21]. Second, we treated the mice with
CpG-ODN at 10 μg/mouse 1 h prior to myocardial I/R and observed that
CpG-ODN-induced protection via a PI3K/Akt dependent mechanism.
In Mathurs' study, these authors treated the mice with CpG-C class
at 100 μg/mouse 24 h before myocardial I/R. The mechanisms are
involved in preconditioning. Our data is consistent with our recent
study showing that administration of CpG-ODN 1826 1 h prior to
induction of trauma hemorrhage (T-H) in mice signiﬁcantly preventedT-H-induced cardiac dysfunction [37]. In addition, we have found that
CpG-ODN 1826 treatment prevented polymicrobial sepsis-induced
cardiac dysfunction (unpublished data). Other studies have shown
that CpG-ODN administration protects the organs in ischemic injury
and septic model through preconditioning mechanisms [14,27,32]. For
example, Stevens et al. reported that systemic administration of CpG-
ODN to mice 72 h prior to brain ischemia reduced ischemic damage up
to 60% in a dose and time dependentmanner through a preconditioning
mechanism [32]. Hyakkoku et al. reported that cerebral infarct volume
in TRL9 knockout mice was similar to that of WT mice, suggesting that
knockout of TLR9 did not protect the brain from ischemic injury [14].
However, Knuefermann et al. reported that in vitro treatment of
isolated wild type cardiac myocytes with CpG-ODN induced a loss of
sarcomeric shortening but not in TLR9 knockout cardiac myocytes [16].
The differences observed in the effect of CpG-ODN treatment on cardiac
myoctyte contractility may be due to use of different experimental
models, i.e., in vitro isolated cardiac myocytes and in vivo cardiac
function. The present study showed that treatment of mice with CpG-
ODN signiﬁcantly decreased myocardial infarct size and improved
cardiac function after ischemia followed by reperfusion up to 14 days.
Administration of the TLR9 antagonist, iCpG-ODN, did not alter I/R-
induced myocardial infarction and cardiac dysfunction, indicating that
Fig. 5. CpG-ODN administration increased TLR9 phosphotyrosine levels and association of the p85 subunit of PI3K with TLR9. H9C2 cells were treated with CpG-ODN or control ODN
for 30 min and untreated cells served as control. Cellular proteins were isolated for Western blot analysis of the levels of phosphorylated Akt (A) and examined for
immunoprecipitation with a speciﬁc anti-TLR9 antibody followed by immunoblots with antibodies to pTyr20 and p85 subunit of PI3K (B). Each group contained four replicates.
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myocardial ischemic injury.
Cardiac myocyte apoptosis plays a role in myocardial I/R injury.
Bcl-2 is an important anti-apoptotic and anti-necrotic molecule while
Bax is proapoptotic mediator. During apoptotic process, Bax protein
undergoes a conformational change and forms homodimers, and then
translocates and integrates into the mitochondrial membrane thereby
facilitating the release of cytochrome c. We have observed that CpG-
ODN administration prevented I/R-decreased Bcl2 levels and atten-
uated I/R-increased Bax levels in the myocardium. The data suggests
that increased Bcl-2 and decreased Bax levels in the myocardium
treated with CpG-ODN could be one of the mechanisms by which the
CpG-ODN protects against myocardial ischemic injury.
Recent studies have shown that CpG-ODN administration in-
creased survival and prevented apoptosis in murine macrophages
[20,29] and neutrophils [15] through activation of the PI3K/Akt sig-
naling pathway. In the present study, we have observed that
administration of CpG-ODN increased the levels of phospho-Akt in
the myocardium following myocardial I/R, indicating that CpG-ODN
treatment activated the PI3K/Akt signaling pathway. It has been well
documented that activation of the PI3K/Akt signaling pathway
protects against I/R-induced cardiac myocyte apoptosis [7,10,19,22].
Activation of PI3K/Akt inhibits Bax conformational change, thus
preventing Bax translocation and integration into mitochondrial
membrane. PI3K/Akt activation also phosphorylates Bim, leading to
dissociation of Bim from BCL2. Numerous studies have demonstrated
that activation of PI3K/Akt may serve as a negative feedback regulator
that prevents excessive innate immune and/or inﬂammatoryresponses during myocardial I/R injury and polymicrobial sepsis
[8,10,19,35]. To determine the mechanisms by which CpG-ODN
treatment activated the PI3K/Akt signaling, we examined whether
there is an association between TLR9 and PI3K following CpG-ODN
administration. We performed in vitro experiments using H9C2
cardiomyoblasts and observed that CpG-ODN administration increased
the levels of phospho-Akt, while PI3K inhibition by LY924002 pre-
vented CpG-ODN-increased Akt phosphorylation. CpG-ODN treatment
rapidly induced TLR9 tyrosine phosphorylation and an association with
the p85 subunit of PI3K. The data suggest that CpG-ODN treatment
increased Akt phosphorylation through induction of TLR9 tyrosine
phosphorylationwhich interactswith PI3K, resulting in activation of the
PI3K/Akt signaling pathway. In vivo experiments showed that either
PI3K inhibition by LY924002, a speciﬁc PI3K inhibitor, or using mice
with genetically defective Akt kinase (kdAkt) abolished CpG-ODN-
induced cardioprotection. This data conﬁrmed that CpG-ODN-induced
cardioprotection is mediated through a TLR9 mediated PI3K/Akt
dependent mechanism.
We have observed that CpG-ODN administration signiﬁcantly
increased the levels of phospho-ERK in the myocardium following
myocardial I/R, suggesting that attenuation of myocardial apoptosis
by CpG-ODN involves activation of ERK signaling. ERK can be
activated by Ref-mediated MEK signaling [23]. The role of Raf/MEK/
ERK signaling pathway in anti-apoptosis has been well demonstrated
[23]. Activation of Raf/MEK/ERK phosphorylates Bad, resulting in its
inactivity. This process allows BCL2 to form homodimers and process
an anti-apoptotic response. Activation of Raf/MEK/ERK also induces

















Fig. 6. Pharmacologic inhibition of PI3K (A) and genetic deﬁciency of Akt (B) abrogated the cardio protection induced by CpG-ODN. (A) Mice were pretreated with the PI3K inhibitor
LY924002 15 min prior to CpG-ODN administration. The hearts were subjected to myocardial ischemia (60 min) followed by reperfusion (4 h). (B) Mice with genetically defective
Akt kinase (kdAkt) showed an abolishment of CpG-ODN-induced cardioprotection. Kinase defective Akt transgenic mice (kdAkt, n=8/group) were pretreated with or without
CpG-ODN 1 h before the hearts were subjected to ischemia (60 min) followed by reperfusion (4 h). Ratios of risk area vs. left ventricle area (RA/LV) and infarct area vs. risk area
(IA/RA) were calculated and are presented in the graph. *Pb0.05 compared with the indicated group. RA = risk area; LV = left ventricle; IA = infarct area; LY = LY924002.
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activation. In addition, the Raf/MEK/ERK and PI3K/Akt signaling
pathways are synergistically regulated and that there is crosstalk
between both signaling pathways [36].
In summary, administration of a TLR9 ligand, CpG-ODN, signiﬁ-
cantly decreased I/R-induced infarct size and improved cardiac
function following myocardial I/R. CpG-ODN-induced cardiopro-
tection is mediated through activation of the PI3K/Akt signaling
pathway. The data suggest that the TLR9 ligand, CpG-ODN, may be a
new approach for management and treatment of acute myocardial
ischemic injury.
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